Clinical Trials

40 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

24 enrolled

Lymphoma, Non-Hodgkin

NCT07261163 2026-05-13

Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

37 enrolled

Lymphoma, Mantle-Cell

NCT07454226 2026-05-13

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

Phase NA Recruiting

92 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07495631 2026-05-13

Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia

Phase NA Recruiting

43 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07584889 2026-05-13

CAR-p40-T

10 enrolled

Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06768905 2026-05-08

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05852717 2026-05-06

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

32 enrolled

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06784726 2026-05-06

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

27 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07374029 2026-05-05

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07564453 2026-05-04

FLOW

101 enrolled

Burkitt Lymphoma

NCT06429150 2026-04-24

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Phase 1 Active not recruiting

20 enrolled

Plasma cell

Multiple Myeloma, Plasmacytoma

NCT03696030 2026-04-23

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

24 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasms, Meningeal Carcinomatosis

NCT03919240 2026-04-21

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

196 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06218602 2026-04-15

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

40 enrolled

Lymphoma

NCT05003895 2026-04-07

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

Phase EARLY_PHASE1 Recruiting

38 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05587543 2026-04-02

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

24 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05378464 2026-04-01

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

28 enrolled

Breast

Breast Neoplasms

NCT06104592 2026-03-31

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

27 enrolled

Lymphoma, Non-Hodgkin

NCT06482905 2026-03-24

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

52 enrolled

CNS

Glioma

NCT07489989 2026-03-24

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07463781 2026-03-13

NEURO_CAR-T

Not yet recruiting

100 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07340853 2026-03-10

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma